Prior to entering clinical trials to confirm in humans the results obtained in preclinical research, a product needs to be correctly defined to ensure the best regulatory strategy and clinical approach. Facilitating a correct definition of the research development and regulatory plan, which involves proper designation of the product, will determine: timings, requirements during later phases, types of meetings to be carried out, the regulatory intermediaries that will be involved, and the possibility of accessing waivers and other mechanisms to accelerate approval that will depend on the medical need to be covered and the nature of the product.
Strategic regulatory inputs can be given from the very beginning for segmentation/niche indication, conditional approval/fast-track, orphan drug designations, and preclinical plans oriented for minimum time to market.
Asphalion can be the ideal regulatory partner during these early stages prior to proceeding to clinical research or in the very early stages of clinical research.
Preclinical development stage Solutions
Early phase regulatory meetings:
Scientific Advice meetings:
Regulatory Tools
Orphan Drugs Designation (ODD)
Paediatric Investigational Plan (PIP)
Support in Clinical Trial Application in EU (preparation and submission), UK and US.
Advanced Therapy Medicinal Products (ATMP) Specific Services:
Call management, presentation and project execution.
Schedule a free meeting!
Discuss your case with our experts and receive a valuable feedback
Share
Why Asphalion?
Asphalion’s team has an extensive academic research experience and broad scientific background in the area of non-clinical and CMC writing for Innovative, Biological, Biotechnological, and Advanced Therapy Medicinal Products. The experience of Asphalion’s team allows the selection of the best regulatory strategy for early developments.
Asphalion has been supporting early development projects for more than 20 years, providing regulatory advice and regulatory strategy for the development and further commercialization of innovative medicinal products and medical devices, helping to minimize the times and maximize the cost efficiency.
Also, we have worked in 15 successful PIPs and 20 ODDs. Our regulatory strategy experts have participated in scientific advices with EMA, as well as National Competent Authorities, such as: PEI, AEMPS, DKMA, CbG, MPA, among others.
Related Resources
Highlights video
Highlights video
Highlights video
Highlights video
Highlights video
Highlights video
Asphalion contributions to the fight against COVID-19
(CTR) No 536/2014
DIA Europe 2025 will focus on sustainability, innovation and collaboration – three key pillars for shaping the future of healthcare. From the environmental impact of pharmaceuticals and of the drug development lifecycle to sustainable partnerships and sustainable healthcare systems, DIA Europe 2025 will be the prime opportunity to discuss how collaboration and innovation can support sustainability in healthcare and each stakeholder’s role in making it happen.
ASPHALION es una empresa internacional líder en Consultoría Regulatoria, Científica y de Seguridad en Ciencias de la Vida. Apoyamos a las empresas en el desarrollo y autorización de medicamentos, desde
ASPHALION és una empresa internacional líder en Consultoria Regulatòria, Científica i de Ciències de la Vida amb 25 anys a l’avantguarda en matèria reguladora. Donem suport a les empreses en
Services
SDGs
As a company committed to sustainability, we follow the UN’s 2030 Agenda and its Sustainable Development Goals.
Memberships & PartnershipS
Quality Management System
Innovative SME
SDGs
As a company committed to sustainability, we follow the UN’s 2030 Agenda and its Sustainable Development Goals.
© Asphalion
Schedule here a free 30-minutes meeting with one of our consultants and tell us about your project, challenges or doubts.
We will be happy to assist you!
